TY - JOUR
T1 - Autologous stem-cell transplantation for multiple myeloma in the era of novel therapies
AU - Parrondo, Ricardo D.
AU - Ailawadhi, Sikander
AU - Sher, Taimur
AU - Chanan-Khan, Asher A.
AU - Roy, Vivek
N1 - Publisher Copyright:
© 2020 by American Society of Clinical Oncology.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.
AB - Despite the evolution of the therapeutic arsenal for the treatment of multiple myeloma (MM) over the past decade, autologous stem-cell transplantation (ASCT) remains an integral part of the treatment of patients with both newly diagnosed and relapsed MM. The advent of novel therapies, such as immunomodulatory agents, proteasome inhibitors, and monoclonal antibodies, has led to unprecedented levels of deep hematologic responses. Nonetheless, studies show that ASCT has an additive effect leading to additional deepening of responses. As the therapeutic agents for MM continue to evolve, the timing, duration, and sequence of their use in combination with ASCT will be crucial to understand to obtain the deepest response and survival benefit for patients with MM. This review aims to discuss the role of ASCT for the management of MM, with a particular focus on the role of ASCT in the context of novel therapies and minimal residual disease.
UR - http://www.scopus.com/inward/record.url?scp=85084458694&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85084458694&partnerID=8YFLogxK
U2 - 10.1200/JOP.19.00335
DO - 10.1200/JOP.19.00335
M3 - Review article
C2 - 32045556
AN - SCOPUS:85084458694
SN - 2688-1527
VL - 16
SP - 56
EP - 66
JO - JCO Oncology Practice
JF - JCO Oncology Practice
IS - 2
ER -